TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31557945

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 3 mg/kg/body mass
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) psychology (given PLA/told CAF)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) pharmacology
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 8
Study: 28641153

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 40 mg for 24 months
Number of subjects: 915

Group type: COMPARATOR
Intervention: Atorvastatin 80 mg for 24 months
Number of subjects: 915
Study: 25977821

Group type: EXPERIMENTAL
Intervention: Aggressive surgical eradication of atypical breast lesions (specific intervention details such as dosage and duration are not available)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery and radiation for DCIS
Number of subjects: 0
Study: 23735736

Group type: EXPERIMENTAL
Intervention: Performance-based financing (PBF) scheme for MNCH services
Number of subjects: 0

Group type: COMPARATOR
Intervention: Technical assistance
Number of subjects: 0
Study: 21392177

Group type: EXPERIMENTAL
Intervention: Ghrelin levels assessment in alcohol-dependent subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Baseline ghrelin levels
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ghrelin gene polymorphisms (Arg51Gln and Leu72Met) assessment
Number of subjects: 0
Study: 19686917

Group type: EXPERIMENTAL
Intervention: Marginal flap
Number of subjects: 31

Group type: COMPARATOR
Intervention: Paramarginal flap
Number of subjects: 31
Study: 17454969

Group type: EXPERIMENTAL
Intervention: Emotion-focused coping
Number of subjects: 553

Group type: EXPERIMENTAL
Intervention: Problem-focused coping
Number of subjects: 553
Study: 15850317

Group type: EXPERIMENTAL
Intervention: Dalteparin (120 U/kg, up to 10,000 U)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 100
Study: 11587680

Group type: EXPERIMENTAL
Intervention: Nissen fundoplication with division of short gastric vessels (SGV)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nissen fundoplication without division of short gastric vessels (SGV)
Number of subjects: 56
Study: 9638988

Group type: EXPERIMENTAL
Intervention: All trans retinoic acid (ATRA) 45 mg/M2/day for 90 days followed by 90 mg/M2 on alternate days till Day 275, combined with low dose cytosine arabinoside (Ara‐C) 10 mg/m2 subcutaneously twice daily for 21 days for a total of 6 cycles.
Number of subjects: 10
Study: 8078983

Group type: EXPERIMENTAL
Intervention: Amitriptylinoxide (120-360 mg daily for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Doxepine (120-360 mg daily for 4 weeks)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Both groups (Amitriptylinoxide and Doxepine)
Number of subjects: 44
Study: 2737231

Group type: EXPERIMENTAL
Intervention: Dimethicone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30514196

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (1000 IU) for 2 weeks in addition to daily subcutaneous human recombinant erythropoietin (2500 IU/kg) for 5 days and IM or IV magnesium sulphate 250 mg/kg within half an hour of birth, subsequently 125 mg/kg at 24 and 48 hours of life.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erythropoietin and magnesium sulphate as in group I but without vitamin D.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (30 healthy neonates).
Number of subjects: 60
Study: 28191917

Group type: EXPERIMENTAL
Intervention: Contingency-management approach
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard care arm
Number of subjects: 35
Study: 25968593

Group type: EXPERIMENTAL
Intervention: Girls (n = 167)
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Post-pubertal boys (n = 83)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Pubertal boys (n = 85)
Number of subjects: 335
Study: 23767801

Group type: EXPERIMENTAL
Intervention: Bayesian latent group model
Number of subjects: 0
Study: 21170708

Group type: EXPERIMENTAL
Intervention: Facilitatory transcranial direct current stimulation (tDCS) applied over the lesioned hemisphere
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation over the lesioned hemisphere
Number of subjects: 0

Group type: COMPARATOR
Intervention: tDCS applied over the non-lesioned hemisphere
Number of subjects: 0
Study: 19101739

Group type: EXPERIMENTAL
Intervention: ART (Atraumatic Restorative Treatment)
Number of subjects: 327

Group type: COMPARATOR
Intervention: ART with Carisolv (chemomechanical caries removal gel)
Number of subjects: 327
Study: 17239474

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (RSG) 4mg daily (increased to 8mg for some subjects)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Insulin glargine (IG) 10 units daily (doses increased until fasting glucose <120mg/dl)
Number of subjects: 40
Study: 14963058

Group type: EXPERIMENTAL
Intervention: Soy protein diet (at least 20 g) and isoflavones (at least 80 mg) for 5 weeks
Number of subjects: 61

Group type: COMPARATOR
Intervention: Olive oil containing active placebo diet
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Both groups (soy protein and placebo)
Number of subjects: 61
Study: 11758227

Group type: EXPERIMENTAL
Intervention: Lupus anticoagulant (LA) IgG from SLE patients
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal IgG
Number of subjects: 0
Study: 9412880

Group type: EXPERIMENTAL
Intervention: Aprotinin (2 x 10(6) kallikrein inhibitor units in CPB prime)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control (untreated group)
Number of subjects: 43
Study: 8118564

Group type: EXPERIMENTAL
Intervention: Radical surgery
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: External-beam radiation
Number of subjects: 144

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 144
Study: 3085551

Group type: EXPERIMENTAL
Intervention: nalbuphine (0.21 mg/kg, intravenous)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: naloxone (0.014 mg/kg, intravenous)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo (normal saline)
Number of subjects: 12
Study: 31246234

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, twice daily
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with prednisone, 5 mg, once daily
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with prednisone, 2.5 mg, twice daily
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Abiraterone acetate, 1000 mg, once daily with dexamethasone, 0.5 mg, once daily
Number of subjects: 164
Study: 30466438

Group type: EXPERIMENTAL
Intervention: Mandolean® training
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 24
Study: 26894653

Group type: EXPERIMENTAL
Intervention: 30 mg febuxostat twice daily
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 40/80 mg febuxostat once daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 24876915

Group type: EXPERIMENTAL
Intervention: Red wine with McDonald's Meal (McD)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Red wine with Mediterranean Meal (MM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Fasting with red wine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All conditions with red wine
Number of subjects: 24

Group type: COMPARATOR
Intervention: McDonald's Meal (McD) without red wine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Mediterranean Meal (MM) without red wine
Number of subjects: 24
Study: 23338259

Group type: EXPERIMENTAL
Intervention: Single‐Bond 2 (Sb2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Single‐Bond 2 + Bond/Scotchbond‐Multipurpose (Sb2B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Single‐Bond 2 + Filtek‐Flow Z350 (Sb2Fl)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Scotchbond‐Multipurpose (SBMP)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clearfil‐S3 (CS3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CS3 + Bond/Clearfil‐SE Bond (CSE3B)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: CS3 + Protect Liner F (CS3PL)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond + Protect Liner F (CSEBPL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: (Control group not specified)
Number of subjects: 80
Study: 20186380

Group type: EXPERIMENTAL
Intervention: Heavyweight mesh (P group)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lightweight mesh (NK group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 50
Study: 17918559

Group type: EXPERIMENTAL
Intervention: Reduced cardiovascular exercise (20 min at approximately 65% maximal heart rate)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Standard cardiovascular exercise (30 min at approximately 80% maximal heart rate)
Number of subjects: 72
Study: 15640324

Group type: EXPERIMENTAL
Intervention: Oral L-arginine supplementation (200 mg x kg(‐1) body weight, t.i.d. for 6 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Single dose of oral L-arginine (200 mg x kg(‐1) body weight)
Number of subjects: 10
Study: 11972568

Group type: EXPERIMENTAL
Intervention: Cultural and self-empowerment group (five-phased intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified cultural group (phase I of the intervention only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional group (control group)
Number of subjects: 0
Study: 10456484

Group type: EXPERIMENTAL
Intervention: (R)-salbutamol
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: rac-salbutamol
Number of subjects: 33

Group type: COMPARATOR
Intervention: (S)-salbutamol
Number of subjects: 33
Study: 8679032

Group type: EXPERIMENTAL
Intervention: Compression ultrasound screening before and after arthroscopic surgery
Number of subjects: 85

Group type: COMPARATOR
Intervention: Patients with DVT risk factors
Number of subjects: 85
Study: 1369702

Group type: EXPERIMENTAL
Intervention: Nicardipine 30 mg t.i.d. for 2 weeks
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Nicardipine at various concentrations (10 nM, 1 microM, 10 mM)
Number of subjects: 8
Study: 36817

Group type: EXPERIMENTAL
Intervention: Cimetidine, 300 mg IV, 2 hr before induction of anesthesia
Number of subjects: 23

Group type: COMPARATOR
Intervention: Glycopyrrolate, 0.3 mg IM, 1 hr before induction of anesthesia
Number of subjects: 23
Study: 31703925

Group type: EXPERIMENTAL
Intervention: Resin-modified ceramic crowns (RMC group)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Metal-ceramic crowns (MC group)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both crown types
Number of subjects: 42
Study: 31198477

Group type: EXPERIMENTAL
Intervention: ELIBA device (lingual elevator by Balercia) used for at least 16 h/day for 6 months
Number of subjects: 50
Study: 28264684

Group type: EXPERIMENTAL
Intervention: Intervention
Number of subjects: 231

Group type: COMPARATOR
Intervention: Control
Number of subjects: 231
Study: 23922258

Group type: EXPERIMENTAL
Intervention: Vibration therapy (VT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 23109266

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBT-I)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 30
Study: 21854609

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 771)
Number of subjects: 1518

Group type: COMPARATOR
Intervention: Control group (n = 747)
Number of subjects: 1518
Study: 20180356

Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg once daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Risedronate 35 mg once a week
Number of subjects: 102
Study: 16540851

Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg x kg(‐1) body weight
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg x kg(‐1) body weight
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 14734986

Group type: EXPERIMENTAL
Intervention: Gauze dressing
Number of subjects: 78

Group type: COMPARATOR
Intervention: No dressing
Number of subjects: 78
Study: 11680666

Group type: EXPERIMENTAL
Intervention: Losartan + Diuretic (L+D)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Calcium Channel Blocker + Diuretic (N+D)
Number of subjects: 37
Study: 9270666

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC) (1.5 g i.v. followed by infusion of 1 mg/kg/min for 30 min, n = 10)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: L-carnitine (1 g i.v. followed by infusion of 0.65 mg/kg/min for 30 min, n = 6)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 28
Study: 8197037

Group type: EXPERIMENTAL
Intervention: Ceftizoxime 1 g plus metronidazole 500 mg intravenously every 12 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Cefoxitin 2 g intravenously every 6 hours
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ampicillin-sulbactam 3 g every 6 hours
Number of subjects: 18
Study: 2454360

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 30975219

Group type: EXPERIMENTAL
Intervention: Synergy drug-eluting stent (DES)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Absorb bioresorbable vascular scaffold (BVS)
Number of subjects: 20
Study: 30430875

Group type: EXPERIMENTAL
Intervention: Combination topical gel of nifedipine (NIF), lidocaine hydrochloride (LDH), and betamethasone valerate (BMV)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Market products (single drug treatments)
Number of subjects: 71
Study: 27435332

Group type: EXPERIMENTAL
Intervention: 20 mg/kg intravenous tranexamic acid (TXA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 70
Study: 24092662

Group type: EXPERIMENTAL
Intervention: Insulin lispro mix 75/25 (LM75/25)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine (GL)
Number of subjects: 0
Study: 22538054

Group type: EXPERIMENTAL
Intervention: Budesonide (3mg) infused locally in the proximal jejunum after administering ketoconazole (doses ranging from 1-128 mg, with an oral dose of 200mg given 12h earlier)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketoconazole (up to 16 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketoconazole (64 mg and above)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ketoconazole (1 mg in mucosa and 50 mg in liver)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Budesonide (0.2mg) administered intravenously
Number of subjects: 8
Study: 19640853

Group type: COMPARATOR
Intervention: Onercept 50 mg and 100 mg
Number of subjects: 297

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 297
Study: 18545216

Group type: EXPERIMENTAL
Intervention: Intranasal heating and humidification in elderly subjects
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (younger subjects)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Study group (elderly subjects)
Number of subjects: 80
Study: 15572317

Group type: EXPERIMENTAL
Intervention: Braced group (off-the-shelf functional knee brace for all cutting, pivoting, or jumping activities for the first year after surgery)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nonbraced group
Number of subjects: 100
Study: 11689747

Group type: EXPERIMENTAL
Intervention: Shoe inserts with varying shape and material (hardness, elasticity)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Shoe inserts
Number of subjects: 206

Group type: COMPARATOR
Intervention: No insert (control condition)
Number of subjects: 206
Study: 9329640

Group type: EXPERIMENTAL
Intervention: In vitro irradiation
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Blood cells of patients subjected to radioiodine therapy
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Blood cells of chronically irradiated volunteers from the Chernobyl region
Number of subjects: 2

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study: 8137969

Group type: EXPERIMENTAL
Intervention: Oil-soluble contrast media
Number of subjects: 2606

Group type: COMPARATOR
Intervention: Water-soluble contrast media
Number of subjects: 2606
Study: 2906317

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 29338917

Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Moderate intensity continuous training
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (no supervised exercise)
Number of subjects: 30
Study: 27020633

Group type: EXPERIMENTAL
Intervention: Red Palm Oil (RPO)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Vitamin E
Number of subjects: 60
Study: 24955450

Group type: EXPERIMENTAL
Intervention: Esomeprazole and flupentixol/melitracen (combination therapy)
Number of subjects: 289

Group type: COMPARATOR
Intervention: Esomeprazole only (monotherapy)
Number of subjects: 289
Study: 23372114

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir monotherapy (DRV/r 800/100 mg once daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Triple therapy with darunavir/ritonavir + 2 NRTIs
Number of subjects: 256
Study: 20566975

Group type: EXPERIMENTAL
Intervention: Laparoscopic anterior 90 degrees partial fundoplication
Number of subjects: 112

Group type: COMPARATOR
Intervention: Laparoscopic Nissen fundoplication
Number of subjects: 112
Study: 18579383

Group type: EXPERIMENTAL
Intervention: Functional Electrical Stimulation (FES) of hamstring muscles during quiet standing in different degrees of crouch
Number of subjects: 5
Study: 16998862

Group type: EXPERIMENTAL
Intervention: Overactive bladder (OAB) severity scores
Number of subjects: 12750

Group type: EXPERIMENTAL
Intervention: Stress urinary incontinence (SUI) severity scores
Number of subjects: 12750

Group type: EXPERIMENTAL
Intervention: SUI severity scores
Number of subjects: 12750

Group type: EXPERIMENTAL
Intervention: Criterion validity of OAB and SUI severity scores
Number of subjects: 12750
Study: 14520123

Group type: EXPERIMENTAL
Intervention: Paroxetine 20 mg/d
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mirtazapine 30 mg/d
Number of subjects: 24
Study: 10926339

Group type: EXPERIMENTAL
Intervention: 800 microg inhaled budesonide per day
Number of subjects: 101

Group type: COMPARATOR
Intervention: 200 microg inhaled budesonide per day
Number of subjects: 101
Study: 8885772

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ampicillin and Placebo
Number of subjects: 60
Study: 1389761

Group type: COMPARATOR
Intervention: Nifedipine 20 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Atenolol 50 mg
Number of subjects: 23

Group type: COMPARATOR
Intervention: Combination of Atenolol and Nifedipine
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 23
Study: 4017661

Group type: EXPERIMENTAL
Intervention: Albumin group (ALB) received 80 g albumin on the day of operation and 20 g albumin for the following three days.
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (NON-ALB) received no extra albumin.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups (ALB and NON-ALB)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Albumin administration
Number of subjects: 26
Study: 30657719

Group type: EXPERIMENTAL
Intervention: Wearing an 18.10-kg weight vest (W)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control condition (C)
Number of subjects: 50
Study: 30413176

Group type: EXPERIMENTAL
Intervention: Mobile app with personalized motivational messages via a recommender system for 6 months
Number of subjects: 200

Group type: COMPARATOR
Intervention: Basic motivational messages
Number of subjects: 200
Study: 27136347

Group type: EXPERIMENTAL
Intervention: 25% Calorie Restriction (CR)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Ad libitum (AL)
Number of subjects: 220
Study: 24331842

Group type: EXPERIMENTAL
Intervention: Milrinone (50 μg/kg/min loading dose followed by 0.6 μg/kg/min continuous infusion)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline (identical volume infused in the same fashion)
Number of subjects: 40
Study: 22251615

Group type: EXPERIMENTAL
Intervention: Tibolone, 2.5 mg daily
Number of subjects: 763

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 763

Group type: EXPERIMENTAL
Intervention: Tibolone
Number of subjects: 763
Study: 20149690

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE) with Bead Block
Number of subjects: 23
Study: 17629829

Group type: EXPERIMENTAL
Intervention: Abciximab (Group A, n=63)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Distal protection system (Group B, n=57)
Number of subjects: 120
Study: 12595513

Group type: EXPERIMENTAL
Intervention: Per-protocol biopsy (n = 30)
Number of subjects: 59

Group type: COMPARATOR
Intervention: No-biopsy (n = 29)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Steroid withdrawal (n = 5)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: CsA discontinuation/reduction (n = 13)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Standard therapy (n = 12)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lowering CsA to low target trough (30 to 70 ng/ml)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Conventional regimen (biopsy patients)
Number of subjects: 59
Study: 11039423

Group type: EXPERIMENTAL
Intervention: Membrane differential filtration treatment, administered five times over a period of 21 weeks.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no treatment).
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Membrane differential filtration treatment.
Number of subjects: 40
Study: 9020990

Group type: EXPERIMENTAL
Intervention: Pirlindole (300 mg/day)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 1547164

Group type: EXPERIMENTAL
Intervention: Hospital admission for rest
Number of subjects: 218

Group type: COMPARATOR
Intervention: Routine outpatient care (Control)
Number of subjects: 218
Study: 2864741

Group type: EXPERIMENTAL
Intervention: 2 g sulphasalazine daily
Number of subjects: 30

Group type: COMPARATOR
Intervention: 500 mg penicillamine daily
Number of subjects: 30